Recursion’s presentation emphasized its differentiated approach compared to traditional biotech companies. While conventional biotechs typically advance one program at a time through a linear ...
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback